GANNEX

gannex-logo

Gannex is dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical-stage drug candidates against three different targets โ€” FASN, THR-ฮฒ, and FXR โ€” and three combination therapies. Founded in 2019, Gannex, a wholly-owned company of Ascletis Pharma.

#People #Website #More

GANNEX

Industry:
Biopharma Biotechnology Pharmaceutical

Founded:
2019-01-01

Address:
New York, New York, United States

Country:
United States

Website Url:
http://www.gannexpharma.com

Total Employee:
1+

Status:
Active

Email Addresses:
[email protected]

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager Apache Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS


Current Employees Featured

jinzi-wu_image

Jinzi Wu
Jinzi Wu Founder, Chief Executive Officer @ Gannex
Founder, Chief Executive Officer

Founder


jinzi-wu_image

Jinzi Wu

Official Site Inspections

http://www.gannexpharma.com

  • Host name: 47.75.123.183
  • IP address: 47.75.123.183
  • Location: Central Hong Kong
  • Latitude: 22.2909
  • Longitude: 114.15
  • Timezone: Asia/Hong_Kong

Loading ...

More informations about "Gannex"

Overview_Gannex Pharma

About GANNEX Who are we? Founded in 2019, Gannex, a wholly-owned company of Ascletis Pharma Inc. (1672.HK), is dedicated to the R&D and commercialization of new drugs in the โ€ฆSee details»

Gannex - Crunchbase Company Profile & Funding

Sub-Organization of . Ascletis . Founded Date 2019; Founders Jinzi Wu; ... Contact Email [email protected]; Gannex is dedicated to the R&D and commercialization of new drugs โ€ฆSee details»

Gannex Pharma Co Ltd. - Drug pipelines, Patents, Clinical trials

Www.gannexpharma.com. Startups | Private Company | 2019 | Zhejiang Sheng, China | < 10 | www.gannexpharma.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational โ€ฆSee details»

Gannex Pharma Co., Ltd. | Reagan-Udall Foundation

To learn more about available clinical trials by Gannex, please visit www.gannexpharma.com, or visit https://clinicaltrials.gov and search by company, disease or medicine. If you have โ€ฆSee details»

Gannex Pharma - Overview, News & Similar companies

Jun 11, 2024 Who is Gannex Pharma. Founded in 2019, Gannex, a wholly-owned company of Ascletis Pharma Inc. (1672.HK), is dedicated to the R&D and commercialization of new drugs โ€ฆSee details»

2024_Gannex Pharma

Jan 23, 2024 Gannex Announces Poster Presentation Describing Positive Interim 12-Week Results from Ongoing 52-Week Phase II Clinical Trial of Once-Daily ASC41 in Patients with โ€ฆSee details»

Gannex Pharma Co., Ltd. | Expanded Access Navigator

To learn more about available clinical trials by Gannex, please visit www.gannexpharma.com, or visit https://clinicaltrials.gov and search by company, disease or medicine. If you have โ€ฆSee details»

Gannex Pharma - VentureRadar

Website: https://www.gannexpharma.com/ Gannex, a wholly-owned company of Ascletis, is dedicated to the R&D and commercialization of new drugs in the field of NASH.See details»

Gannex Pharma Co Ltd.:Company Profile & Technical โ€ฆ

Gannex is a company that provides Drug candidate, Combination therapy and more. Gannex is headquartered in United States North America. Gannex was founded in 2019. and was โ€ฆSee details»

Gannex Pharma Co Ltd. - Massachusetts Institute of Technology

Mar 12, 2023 Discovery Company profile page for Gannex Pharma Co Ltd. including technical research,competitor monitor,market trends,company profile& stock symbolSee details»

Gannex Pharma | CipherBio

Explore Gannex Pharma's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»

Partnership - Gannex Pharma

Partnership. Ascletis was established in 2013 and has been listed on the Hong Kong Stock Exchange since 2018 (1672.HK). Ascletis focuses on the R&D and commercialization of novel โ€ฆSee details»

ๅ…่ดน็š„ๆ–ฐ่ฏๆƒ…ๆŠฅๆ•ฐๆฎๅบ“ - ่ฏๅ“ๆŸฅ่ฏขใ€่ฏๅ“ๆ•ฐๆฎๅบ“ใ€ๅŒป่ฏๆ•ฐๆฎ

BACKGROUND ASC42 is a non-steroidal farnesoid X receptor agonist currently in clinical development for chronic liver diseases, such as nonalcoholic fatty liver disease/nonalcoholic โ€ฆSee details»

Gannex Pharma - Products, Competitors, Financials, Employees ...

Jun 11, 2024 Primary Biliary Cholangitis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Intercept Pharma, Enanta Pharma, COUR Pharma, Novartis, โ€ฆSee details»

Management Team_Gannex Pharma

Management Team_Gannex Pharma is a biotech company developing NASH drugs. Contact us to enroll in a NASH clinical trial.See details»

Gannex Pharma Careers and Employment | Indeed.com

Find out what works well at Gannex Pharma from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles and โ€ฆSee details»

Gannex posts midphase data on NASH asset at center of trade โ€ฆ

Jan 2, 2024 Gannex Pharma has taken a peek at phase 2 data on its nonalcoholic steatohepatitis (NASH) prospect. The Ascletis Pharma subsidiary linked the THRฮฒ agonist to โ€ฆSee details»

2023_Gannex Pharma

Feb 1, 2023 Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D 06/11/2023; Gannex Announces the Completion of Patient โ€ฆSee details»

Pipeline - Gannex Pharma

Pipeline_Gannex Pharma is a biotech company developing NASH drugs. Contact us to enroll in a NASH clinical trial.See details»